In parallel, IL-33/ST2-targeting agents, including ipeceximab (anti-IL-33), astegolimab (anti-ST2), and tozoracimab (anti-IL-33), are in late-stage development for asthma and COPD, with favourable safety profiles [119,120,127] No oncology clinical trials of IL-33/ST2 blockade have yet been published. The gene discussed is IL1RL1; the disease is chronic obstructive pulmonary disease.